Exec Chats

Altoida CEO Marc Jones spoke with Medtech Insight about the company’s investigational digital screening tool for Alzheimer’s and the dire need for better, more accessible precision neurology diagnostics as the global population ages, neurologist shortages worsen, and groundbreaking Alzheimer’s drugs change the treatment paradigm.

In an interview with Medtech Insight, Matt Bettonville, investor at cancer-focused venture firm Yosemite, discussed its criteria for evaluating potential investments in oncology and his outlook on the future oncology landscape.

Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.

Maria Shepherd, co-founder of MedExec Women, a nonprofit that seeks to empower executive leaders in medtech, is preparing to host the group’s fifth annual conference in Boston, which is expected to draw 200 attendees. Shepherd spent more than two decades in the medical device industry before starting consulting firm Medi-Vantage. She talks to Medtech Insight about her own career path, how the industry is changing, and the importance of “grooming” the next generation of young medtech leaders.

Andrew Trister, Verily’s chief medical and scientific officer sat down with Medtech Insight during the recent ViVE conference to talk about how Verily is leveraging AI to address public health issues and global health inequities and the new web-based version of the Onduo platform, the use of GLP-1s to combat chronic diseases, and more. This is the first part of a two-part series on Verily. 

Medtech Insight caught up with Sean Salmon, the president of Medtronic's cardiovascular business, to talk about the long-awaited FDA approval of the Symplicity Spyral renal denervation system, recent approvals of the PulseSelect pulsed field ablation system and extravascular ICD, and the company's plans for transcatheter aortic valve replacement.

Osso VR’s platform for the simulation of orthopedic surgical procedures could solve several issues facing the field, according to CEO Justin Barad.

Exec Chat: Dexcom’s COO Jake Leach joined a panel discussion on the future of biosensing at CES 2024, where biowearables and glucose tech ranked among hot topics. He also spoke to Medtech Insight about plans for the company’s new CGM called Stelo, designed for people with type 2 diabetes who do not use insulin, Dexcom’s work with Apple to enable CGM users, and non-invasive monitoring prospects.

Medtech Insight spoke to Ofer Sharon, CEO of OncoHost, about his company’s PROphet platform, proving a diagnostic’s ability to improve cancer survival, and the slipperiness of involving oneself with pharma.

Exec Chat: UK consumer feedback has led to enhancements to the Lingo biowearable’s companion app to provide deeper, more personalized insight on the meaning of glucose spikes, as well as weeklong challenges to encourage healthy behavioral changes. While awaiting FDA clearance for a planned 2024 launch of Lingo stateside, Abbott also is exploring ways of accessorizing the Lingo sensor to make it more fashionable. Lingo Biowearables leaders Olivier Ropars and Ben Fohner discuss.